Biogen Stock Surges on 36.2% Volume Jump but Ranks 401st in Dollar Trading Volume

On September 16, 2025, , . . equities.

Recent developments highlighted Biogen’s strategic focus on , with updated clinical trial data for its Alzheimer’s drug candidate demonstrating improved biomarker responses. Analysts noted the results, while emphasizing the need for long-term efficacy confirmation. Additionally, regulatory updates indicated no near-term changes to the company’s approval timeline for its key pipeline assets.

To run this back-test accurately I need to pin down a few implementation details that weren’t specified in your request. Please let me know (or confirm my default assumptions) for the points below and I will launch the data pulls and calculations right away.

1. Market universe • Should we look at all U.S. listed common stocks (NYSE + NASDAQ) or a different universe? • ADRs, ETFs and preferreds excluded by default—OK?

2. Ranking & trading convention • Ranking metric: daily dollar trading volume (shares × close) or share volume? • Portfolio construction: equal-weight the 500 selected names each day?

3. Execution timing • Buy at today’s close, hold overnight, sell at tomorrow’s close (standard “T-to-T+1 close” convention)? – If you prefer “next-day open” exits or a different schedule let me know.

4. Transaction costs • Assume zero costs/slippage (default) or would you like to embed e.g. 2 bps per leg?

5. Risk control • No stop-loss / take-profit because positions are closed the next day—OK?

If the defaults above match your intent just say “go ahead” (or adjust any point) and I’ll run the back-test from 2022-01-03 through today.